03rd week of 2016 patent applcation highlights part 8 |
Patent application number | Title | Published |
20160015657 | USE OF EUGENOL TO TREAT BLISTERS - Implementations of a method for treating an affected area of an epidermis having a blister or rash caused by shingles, psoriasis, acne, eczema, bug bits, bee stings, and poison oak comprising applying topically to the affected area of an epidermis a composition comprises eugenol and sesame oil. | 2016-01-21 |
20160015658 | AFFINITY MEDICANT CONJUGATE - In an embodiment of the invention, a composition for treating a cell population comprises an Affinity Medicant Conjugate (AMC). The medicant moiety can be a toxin including an acylfulvene or a drug moiety. The affinity moiety can be an antibody, a binding protein, a steroid, a lipid, a growth factor, a protein, a peptide or non peptidic. The affinity moiety can be covalently bound to the medicant via a linker. Novel linkers that can be directed to cysteine, arginine or lysine residues based on solution pH allow greater flexibility in preserving and/or generating specific epitopes in the AMC. | 2016-01-21 |
20160015659 | TREATMENT OF DEMYELINATING DISORDERS - This invention discloses methods and compositions for the treatment of demyelinating disorders. Specifically, the invention relates to the use guanabenz or guanabenz derivative for treating demyelinating disorders. | 2016-01-21 |
20160015661 | ASSEMBLY COMPRISING AN ABSORBER OF NEAR INFRARED (NIR) LIGHT COVALENTLY LINKED TO AN INHIBITOR OF CARBONIC ANHYDRASE - An assembly comprising an absorber of near infrared (NIR) light having an optical absorption cross section not lower than 100 nm2 covalently linked to an inhibitor of carbonic anhydrase (CA), process for its preparation and its use to hyperthermally target tumours or for treating other conditions in which the CA activity is involved is disclosed. | 2016-01-21 |
20160015662 | METHOD OF ADMINISTRATION OF GAMMA HYDROXYBUTYRATE WITH MONOCARBOXYLATE TRANSPORTERS - One embodiment of the present invention is to improve the safety and efficacy of the administration of GHB or a salt thereof to a patient. It has been discovered that the concomitant administration of an MCT inhibitor, such as diclofenac, valproate, or ibuprofen, will affect GHB administration. For example, it has been discovered that diclofenac lowers the effect of GHB in the body, thereby potentially causing an unsafe condition. Furthermore, it has been discovered that valproate increases the effect of GHB on the body, thereby potentially causing an unsafe condition. | 2016-01-21 |
20160015663 | Methods for Reducing Inter-Patient Variability of Levodopa Plasma Concentrations - The present invention provides methods of reducing the inter-patient variability of levodopa plasma concentrations in a population of Parkinson's disease patients. The methods of the invention comprise pulmonary administration of levodopa at therapeutically effective concentrations such that the inter-patient variability of levodopa plasma concentrations at time periods ranging from about 10 minutes post inhalation to about 60 minutes or more post inhalation have less than a 50% coefficient variation. The methods of the invention are particularly useful for treatment of motor fluctuations which arise as a side effect of L-Dopa therapy. | 2016-01-21 |
20160015664 | Materials and Methods for Improving Lung Function and For Prevention and/or Treatment of Radiation-Induced Lung Complications - The subject invention provides therapeutic compositions and uses thereof for improving pulmonary function. In one embodiment, the therapeutic composition comprises one or more free amino acids selected from lysine, glycine, threonine, valine, tyrosine, aspartic acid, isoleucine, tryptophan, asparagine, and serine; and electrolytes. In one embodiment, the subject invention can be used to prevent or treat long-term lung complications induced by radiation. | 2016-01-21 |
20160015665 | Methods and Compositions for Treating and Identifying Compounds to Treat Age-Related Macular Degeneration Treatment - The present invention provides methods for treating or limiting development of age-related macular degeneration, as well as methods for identifying compound suitable for such use. | 2016-01-21 |
20160015666 | MIXTURE OF FATTY ACIDS FOR USE IN THE TREATMENT OF INFLAMMATORY PATHOLOGIES - This invention relates to a mixture of at least three fatty acids selected from palmitic acid, oleic acid, stearic acid, linoleic acid, alpha-linolenic acid, gamma-linolenic acid, eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), azelaic acid and myristic acid. This invention also relates to the use of the aforesaid mixture in the treatment of inflammatory pathologies. | 2016-01-21 |
20160015667 | METHODS AND COMPOSITIONS FOR PROMOTING THE NEUROLOGICAL DEVELOPMENT OF AN INFANT - The present invention relates to methods for promoting the neurological development of an infant by administration of fatty acids and compositions comprising same, wherein the fatty acids are enriched with respect to docosahexaenoic acid (DHA) content. | 2016-01-21 |
20160015669 | COMPOUND, 1, 3-DIOLEIN-2-LINOLEIN, AND PHARMACEUTICAL PREPARATION AND USE THEREOF - The invention relates to a compound, 1,3-diolein-2-linolein, having a structure of formula (I), which is prepared by a process comprising the preparation of | 2016-01-21 |
20160015670 | COMPOUND, 1-PALMITIN-2-LINOLEIN-3-OLEIN, AND PHARMACEUTICAL PREPARATION AND USE THEREOF - The invention relates to a compound, 1-palmitin-2-linolein-3-olein, having a structure of formula (I), which is prepared by a process comprising the preparation of | 2016-01-21 |
20160015671 | PHARMACEUTICAL COMPOSITION CONTAINING 8 TRIGLYCERIDES, AND PREPARATIONS AND USE THEREOF - The present invention relates to a pharmaceutical composition containing 8 compounds: trilinolein, 1-olein-2,3-dilinolein, 1-palmitin-2,3-dilinolein, 1,3-diolein-2-linolein, 1-palmitin-2-linolein-3-olein, 1,3-dipalmitin-2-linolein, triolein and 1-palmitin-2,3-diolein. The invention also relates to pharmaceutical preparations of this composition and the use thereof in the treatment of tumors and in the immuno-enhancement. | 2016-01-21 |
20160015672 | PHARMACEUTICAL COMPOSITION CONTAINING 13 TRIGLYCERIDES, AND PREPARATIONS AND USE THEREOF - The present invention relates to a pharmaceutical composition containing 13 compounds: 1,3-diolein, 1-linolein-3-olein, 1,2-diolein, 1-olein-2-linolein, 1,2-dilinolein, trilinolein, 1-olein-2,3-dilinolein, 1-palmitin-2,3-dilinolein, 1,3-diolein-2-linolein, 1-palmitin-2-linolein-3-olein, 1,3-dipalmitin-2-linolein, triolein and 1-palmitin-2,3-diolein. The invention also relates to pharmaceutical preparations of this composition and the use thereof in the treatment of tumors and in the immuno-enhancement. | 2016-01-21 |
20160015673 | METHOD FOR LOWERING CHOLESTEROL - The present invention relates to the diagnosis, risk assessment, prevention, and treatment of Senile Dementia of the Alzheimer's Type (SDAT). More specifically the present invention relates to the measurement of ethanolamine phospholipids in human serum. Subsets of these molecules are significantly altered in subjects with pathologically confirmed deposits of β-amyloid versus subjects without β-amyloid deposits and in subjects with a clinical manifestation of dementia consistent with a diagnosis of SDAT versus non-demented controls. Further, the invention relates to the diagnosis of various stages of SDAT, the early detection and prevention of SDAT symptoms, the treatment of SDAT, the differential diagnosis of non-SDAT dementia, and the identification of molecular targets for which chemical or biological treatments can be designed for the therapeutic intervention of SDAT. The present invention also relates to methods of using a molecular diagnostic assay to direct and select the appropriate therapeutic intervention for subjects suffering from dementia. The present invention also relates to small molecules or metabolites that are found to have significantly different abundances between persons with a clinical manifestation of SDAT and normal, non-demented patients. | 2016-01-21 |
20160015674 | Method for Treating Skin Cancer - A method for treating skin cancer including the steps of applying an isothiocyanate functional surfactant to an area affected by skin cancer, wherein the isothiocyanate functional surfactant comprises at least one isothiocyanate functional group associated with an aliphatic and/or aromatic carbon atom of the isothiocyanate functional surfactant. | 2016-01-21 |
20160015675 | Method for Treating Skin Cancer - A method for treating skin cancer including the steps of applying an isothiocyanate functional surfactant to an area affected by skin cancer, wherein the isothiocyanate functional surfactant comprises at least one isothiocyanate functional group associated with an aliphatic and/or aromatic carbon atom of the isothiocyanate functional surfactant. | 2016-01-21 |
20160015676 | Method for Treating Eczema - A method for treating eczema including the steps of applying an isothiocyanate functional surfactant to an area affected by eczema, wherein the isothiocyanate functional surfactant comprises at least one isothiocyanate functional group associated with an aliphatic and/or aromatic carbon atom of the isothiocyanate functional surfactant. | 2016-01-21 |
20160015677 | Method for Treating Eczema - A method for treating eczema including the steps of applying an isothiocyanate functional surfactant to an area affected by eczema, wherein the isothiocyanate functional surfactant comprises at least one isothiocyanate functional group associated with an aliphatic and/or aromatic carbon atom of the isothiocyanate functional surfactant. | 2016-01-21 |
20160015678 | Phenyl Carbamate Compound and a Composition for Preventing or Treating a Psychiatric Disorder Comprising the Same - The present invention relates to a composition for preventing or treating a psychiatric disorder comprising a phenyl carbamate compound and a method for preventing or treating a psychiatric disorder therewith. The present invention provides anti-anxiety activity and protections against seizure and bipolar disorder, such that it may be effectively used for preventing or treating various psychiatric disorders related to mood disorder or resulting convulsion. | 2016-01-21 |
20160015679 | Phenyl Carbamate Compound and a Composition for Preventing or Treating a Nerve Gas-Induced Disease Comprising the Same - The present invention relates to a composition for preventing or treating a nerve gas-induced disease comprising a phenyl carbamate compound and a method for preventing or treating a nerve gas-induced disease therewith. The present invention ensures the enhancement of neuroprotection, such that it is promising for preventing or treating various diseases caused by exposure to nerve gas. | 2016-01-21 |
20160015680 | Phenyl Carbamate Compound and a Composition for Neuroprotection Comprising the Same - The present invention relates to a composition for neuroprotection comprising a phenyl carbamate compound and a method for providing neuroprotection therewith. The present invention ensures the enhancement of neuroprotection, such that it is promising for preventing or treating various diseases associated with neurological injury. | 2016-01-21 |
20160015681 | METHODS OF TREATING LUNG CANCER - The present invention provides methods and compositions for treating non-small-cell lung cancer (NSCLC) by administering a) a composition comprising nanoparticles that comprise paclitaxel and an albumin and b) a platinum-based agent (e.g., carboplatin), wherein the individual has diabetes, has four or more metastatic sites, and/or is at least about 70 years old. | 2016-01-21 |
20160015682 | TETRAHYDROCANNABIVARIN (THCV) FOR USE IN THE PROTECTION OF PANCREATIC ISLET CELLS - The present invention relates to the phytocannabinoid tetrahydrocannabivarin (THCV) for use in the protection of pancreatic islet cells. Preferably the pancreatic islet cells to be protected are beta cells. More preferably the protection of the pancreatic islet cells maintains insulin production at levels which are able to substantially control or improve control of blood glucose levels in a patient. | 2016-01-21 |
20160015683 | SOLID DOSAGE FORM COMPOSITION FOR BUCCAL OR SUBLINGUAL ADMINISTRATION OF CANNABINOIDS - The present invention relates to solid dosage forms of cannabinoid pharmaceutical formulations comprising a solvated cannabinoid for buccal or sublingual administration, and methods of making and using the same. | 2016-01-21 |
20160015684 | COMPOSITIONS COMPRISING BIOREVERSIBLE DERIVATIVES OF HYDROXY N- SUBSTITUTED-2-AMINOTETRALINS, DOSAGE FORMS, AND RELATED METHODS - Described are compositions that may be orally administered that comprise a bioreversible derivative of hydroxy N-substituted-2-aminotetralin or an enantiomer or salt or prodrug thereof, and a pharmaceutically acceptable carrier suitable for oral administration in the amount present, wherein the composition is orally bioavailable when administered to a subject. The bioreversible derivative has an intrinsic lipophilicity C log P value of about 7 to about 11.5. A method comprises oral administering such composition to a human subject in need of hydroxy N-substituted-2-aminotetralin therapy. | 2016-01-21 |
20160015685 | FURO [3, 2-B] PYRR0L-3-0NES AS CATHESPIN S INHIBITORS - A first aspect of the invention relates to a compound of formula (I), or a pharmaceutically acceptable salt, hydrate, complex or pro-drug thereof, | 2016-01-21 |
20160015686 | Methods and Compositions for Increasing Antibiotic Activity - One aspect of the invention provides a method of inhibiting an efflux pump in a bacteria, the method comprising contacting the bacteria with 3,4-dibromopyrrole-2,5-dione, thereby inhibiting the efflux pump. Another aspect provides a method of inhibiting proliferation of a bacteria, the method comprising contacting the bacteria with 3,4-dibromopyrrole-2,5-dione and an antibiotic, thereby inhibiting the proliferation of the bacteria. Another aspect of the invention provides a method of increasing the efficacy of an antibiotic, the method comprising contacting a bacteria with 3,4-dibromopyrrole-2,5-dione and an antibiotic, thereby increasing the efficacy of the antibiotic. Another aspect provides a method of inhibiting development of antibiotic resistance in a bacteria, the method comprising contacting the bacteria with 3,4-dibromopyrrole-2,5-dione and an antibiotic, thereby inhibiting development of resistance to the antibiotic. Another aspect of the invention provides a pharmaceutical composition for treating a bacterial infection comprising an effective amount of 3,4-dibromopyrrole-2,5-dione in a pharmaceutically acceptable excipient. | 2016-01-21 |
20160015687 | TETRAZOLE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS - The present invention relates to novel tetrazole compounds; to processes for their preparation; to pharmaceutical compositions containing the compounds; and to the use of the compounds in therapy to treat diseases for which blocking the Ca | 2016-01-21 |
20160015688 | COMPOUNDS FOR TREATMENT OF CANCER - The present invention relates to pharmaceutical compositions for treating cancer comprising BRAF inhibitors, (e.g. vemurafenib) and/or MEK inhibitor, (e.g. trametinib, RO5068760), in combination with anti-tubulin compounds of the invention or other known tubulin inhibitors, and using such compositions for treating cancer such as melanoma, drug-resistant cancer, and cancer metastasis. | 2016-01-21 |
20160015689 | Topical Localized Isoxazoline Formulation - This invention provides topical localized formulations comprising an isoxazoline compound and a pharmaceutically or veterinary acceptable liquid carrier vehicle comprising N,N-diethyl-3-methylbenzamide as a solvent and an improved method for controlling, and preventing parasite infestation in animals. | 2016-01-21 |
20160015690 | THERAPEUTIC COMPOUNDS - Compounds disclosed herein including compounds of formula I′: | 2016-01-21 |
20160015691 | USE OF MTOR INHIBITORS FOR PREVENTION OF NEUROENDOCRINE TUMOR DEVELOPMENT AND GROWTH - Disclosed are methods and compositions for the prevention or inhibition of the growth of endocrine-related adenomas, neoplasia, or dysplasia in a patient who has been identified as being at risk for developing an endocrine tumor or endocrine cancer. The disclosed methods and compositions include rapamycin, a rapamycin analog, or another such inhibitor of the target of rapamycin (TOR). | 2016-01-21 |
20160015692 | REGIMEN FOR SUPRESSING ORGAN REJECTION - The present invention relates to a method of suppressing organ rejection in a patient receiving an organ transplant by initiating oral treatment with a once-daily extended release tacrolimus dosage form, for example, at an initial dose of from about 0.15 to about 0.20 mg/kg/day within 24 or 48 hours following transplantation. The once-daily extended release tacrolimus dosage form (i) provides low fluctuation and/or swing of tacrolimus, (ii) provides a significantly lower C | 2016-01-21 |
20160015693 | METHODS AND COMPOUNDS FOR PREVENTING AND TREATING A TUMOUR - The invention relates to a method of preventing, inhibiting, arresting or reversing tumourigenesis in a cell as well as a method of inducing apoptosis in a tumour cell. The method includes increasing the amount and/or the activity of a DACT protein, or a functional fragment thereof, in the cell. Also provided is a pharmaceutical composition that comprises a compound of general formula (I) | 2016-01-21 |
20160015695 | TRICYCLIC FUSED THIOPHENE DERIVATIVES AS JAK INHIBITORS - The present invention provides tricyclic fused thiophene derivatives, as well as their compositions and methods of use, that modulate the activity of Janus kinase (JAK) and are useful in the treatment of diseases related to the activity of JAK including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases. | 2016-01-21 |
20160015696 | MICROBICIDAL COMPOSITION COMPRISING AN OCTOXYNOL AND A QUINOLIZIDINE ALKALOID COMPOUND OR A SOURCE THEREOF - The present invention provides microbicidal compositions comprising an octoxynol and a quinolizidine alkaloid compound or a source thereof, and methods of using the compositions. The quinolizidine alkaloid compound has a structure: | 2016-01-21 |
20160015697 | ARYL UREAS WITH ANGIOGENISIS INHIBITING ACTIVITY - This invention relates to methods of using aryl ureas to treat diseases mediated by the VEGF induced signal transduction pathway characterized by abnormal angiogenesis or hyperpermeability processes. | 2016-01-21 |
20160015698 | PHARMACEUTICAL COMPOSITIONS OF DONEPEZIL HAVING SPECIFIC IN VITRO DISSOLUTION PROFILE OR PHARMACOKINETICS PARAMETERS - A timed release pharmaceutical composition comprising donepezil is provided wherein the single dose AUC(14-22) of the said composition administered in the morning is about % to about 30% less than the single dose AUC(2-10) of an immediate release composition of donepezil administered in the night, wherein both the compositions have equivalent dose of donepezil. | 2016-01-21 |
20160015699 | NITROXIDES FOR USE IN TREATING OR PREVENTING DIABETES AND OBESITY - Pharmaceutical compositions are provided that are useful in treating diabetes. The compositions comprise a pharmaceutically acceptable carrier, and an effective therapeutic or prophylactic amount of a nitroxide antioxidant that alters the expression of genes related to diabetes. Methods are also provided for the use of the pharmaceutical compositions in the treatment or prevention of diabetes. In a preferred embodiment, the nitroxide antioxidant is Tempol (4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl). | 2016-01-21 |
20160015700 | 4-CYANO-N-(2-(4,4-DIMETHYLCYCLOHEX-1-EN-1-YL)-6-(2,2,6,6-TETRAMETHYLTETRAH- YDRO-2H-PYRAN-4-YL)PYRIDIN-3-YL)-1H-IMIDAZOLE-2-CARBOXAMIDE FOR THE TREATMENT OF HODGKIN'S LYMPHOMA - The present invention is directed to methods for the treatment of Hodgkin's lymphoma comprising administering to a patient in need thereof, a therapeutically effective amount of 4-cyano-N-(2-(4,4-dimethylcyclohex-1-en-1-yl)-6 -(2,2,6,6-tetramethyltetrahydro-2H-pyran-4-yl)pyridin-3-yl)-1H-imidazole-2-carboxamide as mono-therapy or as combination or co-therapy with one or more chemotherapeutic agent or chemotherapy regimens. | 2016-01-21 |
20160015701 | Methods of Treating Acute Kidney Injury - Methods are provided for treating acute kidney injury in a subject, particularly ischemia-induced kidney injury and/or hypoxia-induced kidney injury. The methods comprise administering to the subject an ETA receptor antagonist, such as atrasentan or a pharmaceutically acceptable salt thereof. Methods of diagnosing and treating such kidney injuries are also provided. Methods of reducing or preventing loss of kidney function and/or renal mass or volume, and methods of delaying progression to chronic kidney disease are also provided. | 2016-01-21 |
20160015702 | AMINOHETEROARYL COMPOUNDS AS MTH1 INHIBITORS - The present invention relates to an (S)-enantiomer of an aminoheteroaryl compound for use in treating and/or preventing cancer in a subject. The invention further relates to a pharmaceutical composition comprising said compound. Another aspect of the invention is directed to an in vitro method for determining the effectiveness of said (S)-enantiomer of an aminoheteroaryl compound, or said pharmaceutical composition, the method comprising the steps of: (a) obtaining a cell or tissue sample from a subject; and (b) determining the subject's NUDT1/MTH1-status; wherein a NUDT1/MTH1-positive cell or tissue sample is indicative of an effective treatment and/or prevention of cancer. In addition, provided herein is a screening method for identifying a target of an (S)-enantiomer of an aminoheteroaryl compound. Furthermore, in context of this invention, the herein described compounds inhibit the biological activity of MTH1. | 2016-01-21 |
20160015703 | NANO- MICRODELIVERY SYSTEMS FOR OROMUCOSAL DELIVERY OF AN ACTIVE INGREDIENT - A composition for oromucosal delivery of at least one active ingredient, more particularly a lipid nano-microdelivery system comprising a nicotine component and/or a flavour component, wherein the nicotine component may be delivered to the oral cavity via absorption through the mucosal membranes thereof and/or wherein the flavour component may be delivered to the oral mucosa by controlled release. | 2016-01-21 |
20160015704 | COMBINATIONS COMPRISING MABA COMPOUNDS AND CORTICOSTEROIDS - A combination which comprises (a) corticosteroid and (b) a dual muscarinic antagonist-β2 adrenergic agonist compound, or any pharmaceutically acceptable salt or solvate thereof. | 2016-01-21 |
20160015705 | TREATMENT OF T-CELL MEDIATED DISEASES - The invention provides a method of treating T-cell mediated diseases and a method of inhibiting the activation of T-cells using certain diketopiperazines. The invention also provides methods of synthesizing diketopiperazines and pharmaceutical compositions comprising certain diketopiperazines. The invention further provides methods of making improved pharmaceutical compositions of proteins and peptides by either increasing or decreasing the content of diketopiperazines in the compositions and the resultant improved pharmaceutical compositions. | 2016-01-21 |
20160015706 | CRYSTALLINE FORMS OF AN ANTIDEPRESSANT COMPOUND - The present invention relates to novel crystalline forms of vortioxetine hydrobromide, in particular three crystalline forms, a process for their preparation, a pharmaceutical composition containing said novel crystalline forms, and a process for the purification of vortioxetine or a salt thereof, comprising the formation of one or more of the novel crystalline forms of vortioxetine hydrobromide described herein. | 2016-01-21 |
20160015707 | METHOD OF PROMOTING REMYELINATION - A method of promoting remyelination in a subject in need thereof includes administering to the subject a therapeutically effective amount of at least one (1,3) Diazole compound, wherein the therapeutically effective amount is the amount effective to induce endogenous oligodendrocyte precursor cell (OPC) differentiation in the subject's central nervous system. | 2016-01-21 |
20160015708 | STABLE DOSAGE FORMS OF IMATINIB MESYLATE - The present invention relates to a stable oral pharmaceutical dosage form comprising imatinib mesylate and one or more pharmaceutically acceptable excipients wherein the amount of imatinib calculated as free base is more than 80% by weight based on the total weight of the oral pharmaceutical dosage form, and wherein the oral dosage form does not show polymorphic conversion after storage at 40° C. and 75% relative humidity for three months. It also relates to processes for the preparation thereof. | 2016-01-21 |
20160015709 | COMPOSITIONS AND METHODS FOR TREATING CANCER AND DISEASES AND CONDITIONS RESPONSIVE TO CELL GROWTH INHIBITION - In alternative embodiments, the invention provides compositions and methods for overcoming or diminishing or preventing Growth Factor Inhibitor resistance in a cell, or, a method for increasing the growth-inhibiting effectiveness of a Growth Factor inhibitor on a cell, or, a method for re-sensitizing a cell to a Growth Factor Inhibitor, comprising for example, administration of a combination of a TBK1 inhibitor and an RTK inhibitor. In alternative embodiments, the cell is a tumor cell, a cancer cell or a dysfunctional cell. In alternative embodiments, the invention provides compositions and methods for determining: whether an individual or a patient would benefit from or respond to administration of a Growth Factor Inhibitor, or, which individuals or patients would benefit from a combinatorial approach comprising administration of a combination of: at least one growth factor and at least one compound, composition or formulation used to practice a method of the invention, such as an NFKB inhibitor, such as a lenalidomide or a REVLIMID™, or IKK inhibitor; or an inhibitor of Galectin-3. | 2016-01-21 |
20160015710 | Methods of Treating Multiple Myeloma and Resistant Cancers - Erastin analogs are useful in treating various cancers, particularly multiple myeloma. Erastin analogs are also useful in treating cancers that are resistant to other anticancer agents. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention. | 2016-01-21 |
20160015711 | CALCIUM PTERIN-6-CARBOXYLATE (CaPTERIN-6-COOH) AS A NOVEL IMMUNO-THERAPEUTIC - Provided herein are methods of treating an inflammatory-based disease or disorder in a subject by administering a composition comprising CaPterin-6-COOH. | 2016-01-21 |
20160015712 | Triazolo[4,5-d]pyrimidine derivatives - Compounds of the formula I | 2016-01-21 |
20160015713 | MODULATORS OF TOLL-LIKE RECEPTORS - Provided are modulators of TLRs of Formula II: | 2016-01-21 |
20160015714 | USE OF A DPP-4 INHIBITOR IN AUTOIMMUNE DIABETES, PARTICULARLY LADA - The present invention relates to methods for treating and/or preventing autoimmune diabetes, particularly LADA, as well as diseases related or associated therewith, comprising the administration of an effective amount of a certain DPP-4 inhibitor, as well as to the use of a certain DPP-4 inhibitor for modifying disease trajectory of autoimmune diabetes (particularly LADA). | 2016-01-21 |
20160015715 | USE OF PDE7 INHIBITORS FOR THE TREATMENT OF MOVEMENT DISORDERS - A method of treating a movement abnormality associated with the pathology of a neurological movement disorder, such as Parkinson's disease or Restless Leg(s) Syndrome by administering a therapeutically effective amount of a PDE7 inhibitory agent. An aspect of the invention provides for the administration of a PDE& inhibitory agent in conjunction with a dopamine agonist or precursor, such as levodopa. In another aspect of the invention, the PDE7 inhibitory agent may be selective for PDE7 relative to other molecular targets (i) known to be involved with the pathology of Parkinson's disease or (ii) at which other drug(s) that are therapeutically effective to treat Parkinson's disease act. | 2016-01-21 |
20160015716 | Fe(III) Complex Compounds For The Treatment And Prophylaxis Of Iron Deficiency Symptoms And Iron Deficiency Anemias - The invention relates to iron(III) complex compounds and pharmaceutical compositions comprising them for the use as medicaments, in particular for the treatment and/or prophylaxis of iron deficiency symptoms and iron deficiency anemias. | 2016-01-21 |
20160015717 | ENHANCED BIMATOPROST OPHTHALMIC SOLUTION - A composition comprising from 0.005% to 0.02% bimatoprost by weight and from 100 ppm to 250 ppm benzalkonium chloride, wherein said composition is an aqueous liquid which is formulated for ophthalmic administration is disclosed herein. A method which is useful in treating glaucoma or ocular hypertension related thereto is also disclosed herein. | 2016-01-21 |
20160015718 | OIL-IN-WATER METHOD FOR MAKING POLYMERIC IMPLANTS CONTAINING A HYPOTENSIVE LIPID - Biocompatible microparticles include an ophthalmically active cyclic lipid component and a biodegradable polymer that is effective, when placed into the subconjunctival space, in facilitating release of the cyclic lipid component into the anterior and posterior segments of an eye for an extended period of time. The cyclic lipid component can be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. Or, the cyclic lipid component can be encapsulated by the polymeric component. The present microparticles include oil-in-water emulsified microparticles. The subconjunctivally administered microparticles can be used to treat or to reduce at least one symptom of an ocular condition, such as glaucoma or age related macular degeneration. | 2016-01-21 |
20160015719 | Method of Producing Testosterone Formulation and Testosterone Formulation Produced Thereby - The present invention is about a method of producing testosterone formulation and the testosterone formulation produced thereby. The method of this invention comprises dissolving testosterone propionate and dibucaine HCl in alcohol, adding particular percentages of polyethylene glycol 400 and polyethylene glycol 4000, and cooling under particular speed to produce the testosterone formulation which has the advantages of moderate viscosity, easy to use and excellent particle consistency. | 2016-01-21 |
20160015721 | Compositions and Methods for Cartilage Repair - Autologous compositions and methods are provided for cartilage repair in patients in need thereof. Some aspects include combinations of platelet-based materials with chondrogenesis inducing agents in the presence or absence of cell-based therapies. | 2016-01-21 |
20160015722 | TREATMENT OF ENDOMETRIOSIS - The present invention provides a composition and method for treating endometriosis which generally, comprises a mixture of anabolic steroids and the administration of same. The first anabolic steroid used is stanozolol used in conjunction with nandralone. The composition is preferably deployed an as injectable liquid suspension. It is also possible to deploy the steroids used herein as an oral administration of the stanozolol alone with an injection of nandralone weekly or as a daily topical nandralone cream. | 2016-01-21 |
20160015723 | COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE EPIDERMAL DISEASES - The present invention provides compositions and methods for use in the treatment of hyperproliferative dermal diseases. Specifically, the present invention teaches pharmaceutical compositions for topical administration consisting essentially of a vitamin D metabolite, calcipotriol, and nicotinamide, which are particularly effective in treating and in the maintenance therapy of psoriasis and other related dermal disorders and diseases. | 2016-01-21 |
20160015724 | NOVEL CRYSTALS AND PROCESS OF MAKING 5-(-METHYL)-2-METHOXY-BENZOIC ACID - The present invention relates to a novel crystals of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid and methods of making the zwitterion of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid. | 2016-01-21 |
20160015725 | METHODS OF CONTROLLING TUMOR BIOENERGETICS NETWORKS - Methods of stimulating anti-tumor activity in a subject with cancer are provided. The methods include administering to a subject in need thereof a low dose low dosage of a composition comprising a molecule that inhibits Hsp90 linked to a mitochondria-penetrating moiety; and administering to the subject an effective amount of an inhibitor of autophagy or glycolysis. | 2016-01-21 |
20160015726 | ACYCLIC NUCLEOSIDE PHOSPHONATE DIESTERS - The present disclosure relates, inter alia, to compositions and methods for treating viral diseases and cancer. There are disclosed lipophilic antiviral and anticancer acyclic nucleoside phosphonate diesters, preparation thereof, and methods of using the compounds to treat viral diseases and cancer. | 2016-01-21 |
20160015727 | PANTOTHENATE DERIVATIVES FOR THE TREATMENT OF NEUROLOGIC DISORDERS - The present disclosure relates to pantothenate derivatives for the treatment of neurologic disorders (such as pantothenate kinase-associated neurodegeneration), pharmaceutical compositions containing such compounds, and their use in treatment of neurologic disorders. | 2016-01-21 |
20160015728 | TARGETING TUMOR CELLS WITH CHEMOTHERAPEUTIC AGENTS CONJUGATED TO MATRIPTASE ANTIBODIES - The present invention relates to matriptase antibodies and immunoconjugates of matriptase antibodies with cytotoxic agents and the use thereof for killing or inhibiting the growth of matriptase-expressing cancer cells, such as those of multiple myeloma and breast cancers. In particular, immunoconjugates comprising a matriptase monoclonal antibody and anticancer agents such as doxorubicin (DOX) are introduced, which are equipotent to anticancer agents used in free form but exhibit significantly reduced cardiotoxicity and almost no adverse effects on normal bone marrow-derived mesenchymal stromal cells that do not express matriptase. The present invention also provides compositions comprising these new immunoconjugates and use of them for treatment of malignancies comprising cells that express matriptase. In addition, administration of a matriptase antibody or immunoconjugates of a matriptase antibody and a cytotoxic agent in combination with administration of an immunomodulatory agent, such as thalidomide or an analog thereof, provides a more effective treatment of these cancers. | 2016-01-21 |
20160015729 | GLYCAN-BASED DRUGS, THERAPIES AND BIOMARKERS - The present disclosure discloses simple and efficient glycan- or carbohydrate-based processes or methods for the rapid identification of biological markers and therapeutic targets especially glycan-related targets of infectious diseases, cancers, autoimmune diseases, allergies, inflammation, toxicity, obesity and/or other disorders of humans, animals, plants and other organisms. Therefore, novel methods and products for the diagnosis, prevention, and treatment of such diseases obtainable based on these therapeutic targets can be developed. | 2016-01-21 |
20160015730 | Treatment of Pulmonary Hypertension with Carbonic Anhydrase Inhibitors - This disclosure relates generally to methods and pharmaceutical compositions useful in treating pulmonary hypertension. In one embodiment, for example, the disclosure provides a method for treating pulmonary hypertension comprising administering a therapeutically effective dose of a carbonic anhydrase inhibitor to a patient in need of treatment. The disclosure finds utility in the fields of medicine and pharmacology. | 2016-01-21 |
20160015731 | A TOPICAL ANTIVIRAL COMPOSITION CONTAINING A LOCAL ANESTHETIC AND METHOD OF MAKING THE SAME - The present invention provides a novel pharmaceutical composition and method of making the same. The composition comprises an effective amount of an antiviral agent and a local anesthetic. The antiviral drug can be sorivudine. The local anesthetic can be lidocaine or its pharmaceutically acceptable salt. Herpes virus infections in humans can be caused by different human herpes viruses, the most common being herpes simplex virus types 1 and 2 (HSV1 and HSV2) and varicella-zoster virus (VZV). | 2016-01-21 |
20160015732 | COMPOSITIONS AND METHODS FOR INDUCING APOPTOSIS - In an aspect, the invention relates to compositions, methods, and kits for inducing apoptosis. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention. | 2016-01-21 |
20160015733 | METHODS AND COMPOSITIONS FOR MODULATING TAU LEVELS - Methods and agents for reducing a level of an acetylated Tau polypeptide in a cell are provided. Methods for treating a tauopathy in an individual are also provided. Also provided is a method for diagnosing a cognitive impairment disorder in an individual. Methods for identifying an agent suitable for treating a tauopathy are also provided. | 2016-01-21 |
20160015734 | Basidiomycete-Derived Cream for Treatment of Skin Diseases - The product according to the present invention is produced in a production process using the mycelium of a mushroom such as | 2016-01-21 |
20160015735 | ANTI-MICROBIAL COMPOSITION - A topical anti-microbial composition and use thereof comprising a quaternized chitosan derivative having a polymerizable organic moiety and an amphoteric surfactant. | 2016-01-21 |
20160015736 | COMPOSITION COMPRISING AT LEAST ONE ALGINATE FOR USE IN TREATMENT AND/OR PREVENTION OF OVERWEIGHT - The present invention relates to a composition in the form of a powder or a viscous paste, and which includes at least one low viscosity alginate having a viscosity of less than about 100 mPaS in a 1 wt % aqueous solution, and at least one high viscosity alginate having a viscosity of more than about 100 mPaS in a 1 wt % aqueous solution. The composition can also include at least one suspending agent. The composition is readily soluble in water such that an aqueous preparation can be prepared without substantive mixing. Also, the aqueous preparation is suitable for use in the treatment and/or prevention of overweight for both therapeutic and non-therapeutic purposes. | 2016-01-21 |
20160015737 | MULTIPURPOSE DENTAL GEL - Some embodiments of the present disclosure include a dental gel formulation for protecting a user's teeth and gums from acid resulting from acid reflux disease or bacterial plaque. The dental gel may include a gel carrier and a treatment ingredient, the treatment ingredient being a member selected from the group consisting of an antibacterial ingredient, an acid neutralizing ingredient, a vitamin, a mineral ingredient, a probiotic, natural extracts and oils, and medication. In some embodiments, the gel carrier may be a poloxamer 407 gel, and the treatment ingredients may include sodium bicarbonate, calcium carbonate, xylitol, and optionally melatonin. | 2016-01-21 |
20160015738 | COMPOSITIONS AND METHODS FOR TREATING INSULIN RESISTANCE AND DIABETES MELLITUS - Provided are electrokinetically-altered fluids (gas-enriched electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide modulation of at least one of cellular membrane potential and cellular membrane conductivity, and therapeutic compositions and methods for use in treating diabetes and diabetes-associated conditions or disorders (e.g., insulin resistance), or symptoms thereof. Provided are electrokinetically-altered ionic aqueous fluids optionally in combination with other therapeutic agents. Particular aspects provide for regulating or modulating intracellular signal transduction associated with said inflammatory responses by modulation of at least one of cellular membranes, membrane potential, membrane proteins such as membrane receptors, including but not limited to G-Protein Coupled Receptors (GPCR), and intercellular junctions (e.g., tight junctions, gap junctions, zona adherins and desmasomes). Other embodiments include particular routes of administration or formulations for the electrokinetically-altered fluids (e.g., electrokinetically-altered gas-enriched fluids and solutions) and therapeutic compositions. | 2016-01-21 |
20160015739 | USING AQUEOUS OXYGENATION TO IMPROVE ANIMAL HEALTH & WELLNESS - Dispersing gas in a liquid provides a mixture of saturated, supersaturated or hypersaturated solution to provide a suspension of bubbles containing gas therein into which animal tissue is immersed for health or wellness treatment. A two-phase mixture is provided with dissolved gas as a suspension of microbubbles. Methods for making, maintaining, and using the two-phase mixture are provided. Gas molecules may be introduced into a liquid at high velocity under elevated pressure to form a supersaturated solution that retains the gas, preferably oxygen, in solution when exposed to ambient conditions. | 2016-01-21 |
20160015740 | CHROMIUM-CONTAINING COMPOSITIONS FOR IMPROVING ENDOTHELIAL FUNCTION AND CARDIOVASCULAR HEALTH - Chromium-three cation containing compositions in combination with | 2016-01-21 |
20160015741 | Cerium Oxide Nanoparticles Accelerate the Decay of Peroxynitrite (ONOO-) - Disclosed herein are methods and materials that may be implemented to scavenge a potentially destructive free radical, peroxynitrite. Specifically exemplified are cerium based nanoparticles that react with and reduce peroxynitrite. The discoveries disclosed herein reveal several therapeutic uses of such peroxynitrite reactive particles. | 2016-01-21 |
20160015742 | TRANSCRANIAL BURST ELECTROSTIMULATION APPARATUS AND ITS APPLICATIONS - The invention relates to a method of using metal nanoparticle or metallic particle to promote neurite outgrowth and treat and/or prevent neurological disorders. Particularly, the method of the invention uses gold nanoparticles or gold particles to promote neurite outgrowth and treat and/or prevent neurological disorders. | 2016-01-21 |
20160015743 | METHODS FOR TREATING CANCER - Disclosed herein are methods for treating cancer, such as a cyclin D1-overexpressing cancer, including administering to a subject in need of such treatment a composition comprising a therapeutically effective amount of an agent that mediates downregulation of cyclin D1 and/or increases sumoylation of cyclin D1. | 2016-01-21 |
20160015744 | Methods for Treating Acne Vulgaris - Methods for treating acne vulgaris include providing a solution having a peroxide compound, the solution having an antimicrobial effect for reducing bacteria that cause acne vulgaris; topically administering a therapeutically effective amount of the solution to the patient; and once administered, exposing the solution to a wavelength of light that creates a synergistic antimicrobial effect with the solution and enhances the antimicrobial effect of the solution, thereby further reducing or eliminating the bacteria that cause acne vulgaris. The methods may decrease lesions and associated inflammation in patients infected with acne vulgaris, | 2016-01-21 |
20160015745 | Formulations of Antimicrobial, Antiviral, and Antineoplastic Compounds In Combination With Certain Wavelengths of Light - Formulations of antimicrobial, antiviral, and antineoplastic compounds in combination with certain wavelengths of light include a solution that includes an oxidizer; the solution having an initial therapeutic effectiveness; and a light of a predetermined frequency that that undergoes a synergistic reaction with the oxidizer, thereby enhancing the initial therapeutic effectiveness of the solution. A method of drug-enhancement includes providing a drug that includes hydrogen peroxide and a therapeutic chemical, the drug having an initial therapeutic effectiveness; and applying light having a predetermined frequency of light that has a synergistic reaction with the drug, thereby enhancing the initial therapeutic effectiveness of the drug. | 2016-01-21 |
20160015746 | PHOSPHORUS-SPARING NUTRITIONAL COMPOSITION - A nutritional composition comprises (a) one to a plurality of physiologically acceptable calcium salts and/or chelates and (b) one or more phosphorus-containing components, such as phosphate salts, and/or phosphorus-rescuing components, such as phytase. The composition is useful for phosphorus-sparing calcium supplementation of the diet of a human subject, and for treatment of a low bone density condition in a human subject in need thereof. | 2016-01-21 |
20160015747 | ANTI-GLYCATION METHODS AND COMPOSITIONS - The present invention comprises compositions that provide anti-glycation activity comprising a mineral extract composition or a mogroside/mineral extract composition or a mogroside composition. Such compositions are useful for methods of preventing, treating and inhibiting the effects of glycation in the body. The methods of the present invention comprise use of anti-glycation composition for the treatment and prevention of glycation related conditions including diabetes, atherosclerosis, arthritis, mental conditions and vision impairment. | 2016-01-21 |
20160015748 | Activation of Innate Immunity by miRNA for Cancer and Infection Treatment - Methods and compositions involving miR-122, miR-15 | 2016-01-21 |
20160015749 | ENGAGER CELLS FOR IMMUNOTHERAPY - Embodiments concern methods and/or compositions related to immunotherapy for cancer. In particular embodiments, engager immune cells harbor a vector that encodes a secretable engager molecule. In particular cases, the engager molecule has an activation domain and an antigen recognition domain. In some embodiments, the engager molecules further comprise a cytokine or co-stimulatory domain, for example. | 2016-01-21 |
20160015750 | VASCULAR-TARGETED T-CELL THERAPY - Embodiments of the invention provide for cell therapy for cancers having a TEM1 or TEM8 antigen. Certain embodiments provide for cell therapy that targets tumor vasculature, including the tumor vascular bed, for example. In specific embodiments, TEM1- and/or TEM8-specific chimeric antigen receptors are employed. | 2016-01-21 |
20160015751 | METHOD FOR ENHANCING A FUNCTION OF A T CELL - Disclosed is a method for enhancing the function of a T cell, which is characterized by inhibiting the expression of programmed death-1 ligand 1 (PD-L1) and/or programmed death-1 ligand 2 (PD-L2) in the T cell. Also disclosed is a function-enhanced T cell which is produced by the function enhancement method. Further disclosed is a therapeutic agent comprising the function-enhanced T cell. The T cell can enhance an immune response to cancer, and is useful in an immunotherapy effective for cancer and the treatment or prevention of infectious diseases and autoimmune diseases. | 2016-01-21 |
20160015752 | TREATMENT AND PROPHYLAXIS OF RADIATION DERMATITIS - The present disclosure relates to topical formulations comprising purified water, milk protein fluid and thickener, in particular a hydrogel and a lotion, and their use in treatment of radiation dermatitis, in particular in a two-step process for the treatment of radiation dermatitis. | 2016-01-21 |
20160015753 | SPINAL DISK REGENERATIVE COMPOSITION AND METHOD OF MANUFACTURE AND USE - The present invention provides a novel way to replenish the disc using retooled disc compositions to repair degenerative discs. There is no better source of proteoglycans than the actual disc material ( | 2016-01-21 |
20160015754 | SPINAL DISK REGENERATIVE COMPOSITION AND METHOD OF MANUFACTURE AND USE - The present invention provides a novel way to replenish the disc using retooled disc compositions to repair degenerative discs. There is no better source of proteoglycans than the actual disc material ( | 2016-01-21 |
20160015755 | SPINAL DISK REGENERATIVE COMPOSITION AND METHOD OF MANUFACTURE AND USE - The present invention provides a novel way to replenish the disc using retooled disc compositions to repair degenerative discs. There is no better source of proteoglycans than the actual disc material ( | 2016-01-21 |
20160015756 | CELL THERAPY: A METHOD AND A COMPOSITION FOR TREATING DIABETES - A method of increasing beta-islet cells from pancreases of rabbits and a composition for transplantation of beta-islet cells isolated and cultured from rabbit pancreases to promote natural insulin production among diabetic patients. | 2016-01-21 |
20160015757 | MICROBIAL COMPOSITIONS COMPRISING RUMEN MICROFLORA AND USES THEREOF - A method of mimicking a phenotype of a first ruminating animal in a second ruminating animal is disclosed. The method comprises administering to the second ruminating animal a microbial composition comprising a plurality of microbes having a signature which is statistically significantly similar to the microbial signature of a rumen microbiome of the first ruminating animal, wherein the first and the second ruminating animal are of identical species, thereby mimicking the phenotype of the first ruminating animal in the second ruminating animal. | 2016-01-21 |
20160015759 | COMPOSITIONS AND METHODS FOR TREATING AN IMMUNODEFICIENCY VIRUS INFECTION - The present disclosure provides an interfering, conditionally replicating human immunodeficiency virus (HIV) construct; infectious particles comprising the constructs; and compositions comprising the construct or the particle. The constructs, particles, and compositions are useful in methods of reducing HIV viral load in an individual, which methods are also provided. | 2016-01-21 |
20160015760 | NEWCASTLE DISEASE VIRUSES AND USES THEREOF - Described herein are chimeric Newcastle disease viruses engineered to express an agonist of a co-stimulatory signal of an immune cell and compositions comprising such viruses. Also described herein are chimeric Newcastle disease viruses engineered to express an antagonist of an inhibitory signal of an immune cell and compositions comprising such viruses. The chimeric Newcastle disease viruses and compositions are useful in the treatment of cancer. In addition, described herein are methods for treating cancer comprising administering Newcastle disease viruses in combination with an agonist of a co-stimulatory signal of an immune and/or an antagonist of an inhibitory signal of an immune cell. | 2016-01-21 |
20160015761 | USE OF PHOTOSYNTHETIC SCAFFOLDS IN TISSUE ENGINEERING - The present invention is concerned with a photosynthetic scaffold that delivers oxygen and its uses for tissue engineering and the treatment of ischemia. | 2016-01-21 |